Header Logo

Connection

ELIZABETH SHPALL to Receptors, Antigen, T-Cell

Back to Details
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Receptors, Antigen, T-Cell.
ELIZABETH SHPALL
Connection Strength
1.941
Receptors, Antigen, T-Cell
  1. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62.
    View in: PubMed
    Score: 0.379
  2. CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep. 2013 Mar; 8(1):60-70.
    View in: PubMed
    Score: 0.277
  3. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.
    View in: PubMed
    Score: 0.168
  4. CAR-Transduced Natural Killer Cells. Reply. N Engl J Med. 2020 05 07; 382(19):1866-1867.
    View in: PubMed
    Score: 0.114
  5. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:433-444.
    View in: PubMed
    Score: 0.106
  6. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 03; 25(3):e76-e85.
    View in: PubMed
    Score: 0.103
  7. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
    View in: PubMed
    Score: 0.093
  8. Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Mol Imaging Biol. 2016 12; 18(6):838-848.
    View in: PubMed
    Score: 0.090
  9. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016 08; 18(8):985-994.
    View in: PubMed
    Score: 0.087
  10. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):559-64.
    View in: PubMed
    Score: 0.078
  11. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22.
    View in: PubMed
    Score: 0.077
  12. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012 May; 23(5):444-50.
    View in: PubMed
    Score: 0.064
  13. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy. 2024 Nov; 26(11):1331-1340.
    View in: PubMed
    Score: 0.038
  14. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
    View in: PubMed
    Score: 0.035
  15. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol. 2022; 13:1032397.
    View in: PubMed
    Score: 0.034
  16. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.
    View in: PubMed
    Score: 0.033
  17. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022 07 01; 107(7):1555-1566.
    View in: PubMed
    Score: 0.033
  18. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors? Biol Blood Marrow Transplant. 2020 10; 26(10):1759-1769.
    View in: PubMed
    Score: 0.029
  19. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
    View in: PubMed
    Score: 0.028
  20. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
    View in: PubMed
    Score: 0.022
  21. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63.
    View in: PubMed
    Score: 0.020
  22. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013 Feb 01; (72):e50070.
    View in: PubMed
    Score: 0.017
  23. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy. 2010 Oct; 12(6):713-20.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.